GNBT - Generex Biotechnology Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
10.20
+0.50 (+5.15%)
At close: 3:17PM EDT
Stock chart is not supported by your current browser
Previous Close9.70
Open9.70
Bid0.00 x 0
Ask0.00 x 0
Day's Range9.50 - 10.50
52 Week Range1.76 - 11.90
Volume3,684
Avg. Volume5,124
Market Cap10.895M
Beta (3Y Monthly)0.16
PE Ratio (TTM)2.60
EPS (TTM)3.93
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • Business Wireyesterday

    Generex Confirms & Clarifies 20:1 Common Stock Dividend

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today confirmed its previously announced plan to issue a 20:1 stock dividend. The announcement today includes a clarification of the stock dividend process and how it is different from a forward spilt. On October 10, 2018 the Company announced that its Board of Directors had approved the issuance of 20 shares of common stock for every one share of issued and outstanding common stock.

  • Business Wire6 days ago

    Generex Announces Launch of NuGenerex Distribution Solutions

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce the launch of NuGenerex Distribution Solutions, and the commencement of business operations enabled through the acquisition of certain operating assets of Veneto Holdings, L.L.C., as announced on October 9, 2018. NuGenerex Distribution Solutions (NDS), an affiliate of Generex, has begun implementing its plan to provide essential management services to an extensive network of top-tier ancillary service providers, including pharmacies, laboratories, diagnostic imaging centers, and durable medical equipment manufacturers. Generex Chief Operating Officer, Terry Thompson, stated, “Generex will be providing centralized insurance adjudication, product procurement, and other support services that allow the acquired assets to increase revenue and service quality, decreasing costs, while focusing on providing better patient care.

  • Business Wire11 days ago

    Generex Announces Anthony S. Crisci, Esq., CPA as General Manager, Chief Compliance Officer and Corporate Counsel of its New, Wholly-Owned Subsidiary, NuGenerex Distribution Solutions

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that Anthony S. Crisci, Esq., CPA has joined the Company as the General Manager, Chief Compliance Officer & Corporate Counsel for all of NuGenerex’s distribution efforts, including its newly acquired eight (8) pharmacies and laboratory from Veneto Holdings, L.L.C., to lead the Company in building an end-to-end solution for pharmacy and health management services. Mr. Crisci, a member of the New York and New Jersey Bar associations, as well as a licensed CPA, has built a stellar career as a business legal executive across a number of regulated industries.

  • Business Wire13 days ago

    Generex Announces Stock Dividend

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced its plan to issue a stock dividend. The Company’s Board of Directors has approved the issuance of 20 shares of common stock for every one share of issued and outstanding common stock. As at the date hereof, there are 1,068,100 shares of the Company’s common stock issued and outstanding.

  • Business Wire14 days ago

    Generex Announces Closing of First Tranche Acquisition of Operating Assets

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (“Generex”) today provided further details in respect of its October 3, 2018 acquisition of certain operating assets of Veneto Holdings, L.L.C. (“Veneto”), a private company, and certain of its affiliated entities (collectively, the “Veneto Group”). The Veneto Group is engaged in the business of providing (i) certain specialty pharmacy services and products, (ii) surgical products and services, (iii) diagnostic testing for screening human blood, urine and/or saliva samples for the presence of narcotics, medications, alcohol and other drugs and substances, (iv) durable medical equipment services, and (v) similar ancillary healthcare services such as management services for the foregoing businesses (collectively, the “Business”).

  • Business Wire18 days ago

    Generex Biotechnology Provides Update on AE37 Immuno-Therapeutic Clinical Development Program

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the Company, in conjunction with its research collaborators Merck and the NSABP Foundation, will file an IND in October to initiate A Phase II Clinical Trial of Pembrolizumab (Keytruda®) in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer. It is anticipated that the trial will initiate sites in the fourth quarter and begin enrolling patients in the first quarter of 2019.

  • Business Wire19 days ago

    Generex Biotechnology Corporation Shareholder Alert

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the Company has closed the first tranche of a purchase of the going concern assets of a business providing (i) certain specialty pharmacy services and products, (ii) surgical products and services, (iii) diagnostic testing for screening human blood, urine and/or saliva samples for the presence of narcotics, medications, alcohol and other drugs and substances, (iv) durable medical equipment services, and (v) similar ancillary healthcare services, and the provision of management services for the foregoing businesses. Furthermore, in the same transaction, Generex has committed to closing on the acquisition of additional operating assets within the next 30 days that will significantly enhance revenue and establish a platform for growth that is projected to become a lucrative enterprise through expansion from the three states currently served to an additional 23 states targeted in the expansion plan.

  • Business Wire27 days ago

    Generex Launches NuGenerex Medical Marketing

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce the launch of NuGenerex Medical Marketing (NMM) (https://nugenerexmedicalmarketingllc.com/) to provide in-depth patient health management services, including patient identification, acquisition and onboarding, as well as ongoing patient support services for chronic care management through a dedicated call-center. Generex is establishing NMM as an integrated sales and marketing backbone to support the previously announced plan to establish the Company as a presence in the U.S. direct-to-consumer pharmaceuticals business through a multi-channel acquisition strategy.

  • Business Wirelast month

    Generex Subsidiary Hema Diagnostic Systems, LLC dba NuGenerex Diagnostics Announces Filing of a European CE Marking Application

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that its subsidiary, Hema Diagnostic Systems, LLC dba NuGenerex Diagnostics (www.nugenerexdiagnostics.com), has filed an application for European Economic Area (EEA) CE Marking of its newly developed point-of-care platform, the Express II, in respect of the commercialization of the device for the rapid testing of syphilis antibodies as part of international diagnostic testing algorithms. CE Marking signifies that products sold in the EEA have been assessed to meet high safety, health, and environmental protection requirements and ensures free movement of products within the 30 EEA countries.

  • Business Wire2 months ago

    Generex Biotechnology to Present Overview of Immuno-Oncology Development Program at Summit in Boston, MA

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that Richard Purcell, the Company’s Executive Vice President of Research & Development will participate in a panel discussion at the Cambridge Healthtech Institute’s Immuno-Oncology Summit at the Seaport World Trade Center in Boston, MA (https://www.immuno-oncologysummit.com/) on August 30, 2018. The panel discussion will focus on current trends and future prospects for immunotherapy in the treatment of cancer.

  • Business Wire4 months ago

    Generex Biotechnology Corporation Announces the Filing of a Patent for its New Diagnostic Point-of-Care Platform, the Express II

    Hema Diagnostic Systems, LLC dba NuGenerex Diagnostics (www.hemadiagnosticsystems.com), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), announced today the filing of a patent on its new diagnostic qualitative point-of-care platform, the Express II. Analytes that can be measured by this new device include antigens or antibodies and protein biomarkers which are found in infectious diseases, metabolic diseases and in a host of other medical conditions. The Express II has major advantages over other point-of-care devices because of its simplicity of use, which include fewer steps of operation, the elimination of loops or pipettes for transferring samples, the elimination of unnecessary sample pickup pads, and its ability to be utilized in professional settings, remote field use and for individual in-home use directly by consumers who can conduct the test by themselves in privacy.

  • Business Wire4 months ago

    Generex Announces Terry Thompson as Chief Operating Officer

    Generex Biotechnology Corporation (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased and proud to announce that Terry Thompson has joined the Company’s executive management team as Chief Operating Officer to lead the Company’s efforts in building an end-to-end solution for patients, to include pharmacy, clinical laboratories, pharmacogenomic testing (PGx), compounding, drug manufacturing, and other ancillary health management services. Mr. Thompson brings a wealth of experience and expertise in healthcare, providing executive leadership in pharmacy benefits management, network administration, claims processing, and distribution & logistics for drugs, durable medical equipment (DME), and infusion therapy, as illustrated by his impressive 35-year career.

  • Business Wire10 months ago

    Generex CEO Provides 2017 Year-End Summary to Stakeholders

    Generex Biotechnology Corporation today issued the following letter from the Company’s President & Chief Executive Officer, Joseph Moscato, providing his fellow stockholders with a summary of the Company’s initiatives and achievements over the course of 2017.

  • Business Wire10 months ago

    Generex Provides Access Information for Investor Conference Call Scheduled for January 4, 2018

    Generex Biotechnology Corporation today announced the following access information for its investor conference call, to be hosted by President & Chief Executive Officer Joseph Moscato, and his management team, tomorrow, Thursday, January 4, 2018, at 10:30 a.m.

  • Business Wire10 months ago

    Generex Announces Initial Pharmacy Acquisitions & Plans for Broader Acquisitions Strategy

    Generex Biotechnology Corporation today announced that it has completed the acquisition of two pre-operational retail pharmacy operations.

  • Business Wire10 months ago

    Generex Confirms Receipt of $700,000 USD License Fee from Shenzhen BioScien Pharmaceuticals

    Generex Biotechnology Corporation today confirmed its receipt of the $700,000 USD up-front license fee payable by Shenzhen BioScien Pharmaceuticals Co.

  • Business Wire10 months ago

    Generex Announces Investor Conference Call; Management to Provide Update on Initiatives & Strategic Plans

    Generex Biotechnology Corporation today announced that it will hold an investor conference call at 10:30 a.m.

  • Business Wire11 months ago

    Generex Announces Collaboration with Shenzhen BioScien Pharmaceuticals to Develop and Commercialize the AE37 Immunotherapeutic Vaccine for the Treatment of Prostate Cancer in China

    Generex Biotechnology Corporation today announced that its wholly-owned subsidiary, Antigen Express, Inc.

  • Business Wire11 months ago

    Generex Announces Upgrade to OTCQB® Venture Market

    Generex Biotechnology Corporation today announced that trading in its common stock will be upgraded to the OTCQB® Venture Market on November 30, 2017 after a successful application to up-list from the OTC Pink Market.

  • Business Wire11 months ago

    Generex Announces Results of Annual Stockholders’ Meeting

    Generex Biotechnology Corporation today announced the results of the annual meeting of the Company’s stockholders held on November 21, 2017.